This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

IC14

Implicit Bioscience, Ltd.

Drug Names(s): IC14

Description: IC14 is a newly developed recombinant chimeric mAb directed against CD14. IC14 prevents LPS-induced hypotension and reduced plasma cytokine levels.

Deal Structure: Icos has entered into a sublicensing arrangement with Johnson & Johnson and The Rockefeller University under which technology relating to IC14, developed by Dr. Richard Ulevitch at The Scripps Clinic and Research Foundation and Dr. Samuel Wright at The Rockefeller University, was sublicensed to Icos. Under this arrangement, Icos received a sublicense to the intellectual property relating to IC14 in exchange for royalty and future milestone payments based on development of this product candidate. Icos has exclusive rights to a portfolio of patents for the production and commercialization of IC14.

In January 2007, Lilly completed its acquisition of ICOS Corporation. As a result of closing the transaction, Lilly has acquired all of the outstanding shares of ICOS common stock at a price of $34 per share, for a total of approximately $2.3 billion.

In February 2009, Implicit Bioscience announced the acquisition of IC14 from Eli Lilly. Implicit has paid an undisclosed consideration...See full deal structure in Biomedtracker

Partners: Johnson & Johnson Eli Lilly & Company


IC14 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug